Delivery Order SPE2DR25D3301-SPE2DR26F19SU
Award Date 12/18/25
Potential Completion Date 1/12/26
Potential Value $76K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $53,535.55 delivery order to AmerisourceBergen Drug Corp for 4,569,471,727 units of Ocrevus 300 mg/10 mL vials on September 16, 2025, with an ultimate completion date of October 7, 2025. This competitively awarded, firm fixed price contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Ocrevus is a monoclonal antibody treatment used primarily for multiple sclerosis, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Ocrevus 300 mg/10 mL vials totaling $25,332.96 with completion targeted for December 31, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $75,998.88 and firm fixed pricing. This non-set-aside, competitively awarded delivery order is scheduled for completion by December 3, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Ocrevus is a prescription pharmaceutical used primarily in the treatment of multiple sclerosis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials, with a ceiling value of $24,038.58 and a firm fixed price structure. This delivery order is a non-set-aside competitive award with a completion deadline of December 1, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Ocrevus is a monoclonal antibody used primarily to treat...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $63,332.40 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials on November 28, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 19, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. Ocrevus is a specialized pharmaceutical product used in the treatment of multiple sclerosis and represents part of the...
- The Defense Logistics Agency awarded a delivery order valued at $48,077.16 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This non-set-aside, firm fixed price delivery order is scheduled for completion by September 3, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. Ocrevus is a specialty pharmaceutical product used in the treatment of multiple sclerosis, reflecting the critical role AmerisourceBergen plays in supplying...
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $25,332.96 and firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of December 5, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $52,433.04 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and requires completion by December 2, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Ocrevus is a specialty pharmaceutical product used in the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $48,077.16. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 28, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...